title: N-acetyltransferase 2 phenotype and risk of esophageal cancer: a meta analysis.
abstract: N-acetyltransferase 2 (NAT2) gene encodes a phase II enzyme taking part in detoxification of aromatic amines. Published studies have demonstrated that N-Acetyltransferase 2 (NAT2) phenotype is a risk factor of various cancers. Many studies have investigated the association between NAT2 phenotype and susceptibility to esophageal cancer but yielded controversial results. To derive a more precise estimation of this association, a meta-analysis was performed. Electronic databases (Pubmed/Medline, ISI Web of Science and China National Knowledge Infrastructure) in English and Chinese were searched. A total of 5 articles including 476 cases and 1,093 controls were included in this meta-analysis. Odds ratio (OR) with 95% confidence interval (95% CI) was used to evaluate intensity of associations. Pooling studies together, NAT2 slow acetylator phenotype was a significant risk factor of esophageal squamous cell cancer (OR=1.35, 95% CI=1.03-1.77, n=5 studies) but not esophageal adenocarcinoma (OR=0.97, 95% CI=0.47-2.04, n=2 studies). There was a significant association between NAT2 acetylator phenotypes and ESCC in South Asian populations (OR=1.51, 95% CI=1.03-2.20), but not in East Asian populations (OR=1.19, 95% CI=0.80-1.77). Significant association between NAT2 acetylator phenotypes and esophageal cancer was found in population-based control subgroup (OR=1.63, 95% CI=1.07-2.50) but not in hospital-based control subgroup (OR=1.19, 95% CI=0.84-1.69). There is a significant association between NAT2 acetylator phenotype and esophageal cancer in both smokers (OR=1.681, 95% CI=1.179-2.395) and non-smokers (OR=1.614, 95% CI=1.173-2.222). In conclusion, NAT2 slow acetylator phenotype was a significant risk factor of ESCC in Asian populations.
authors.affiliation: Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China Key Laboratory of Carcinogenesis and Translational Research, Departments of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Ruo-Lan
authors.initials: RL
authors.lastname: Ma
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research, Departments of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Li
authors.initials: L
authors.lastname: Min
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research, Departments of Epidemiology, Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Duo
authors.initials: D
authors.lastname: Chen
authors.affiliation: Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Tao
authors.affiliation: Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Ge
authors.affiliation: Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
authors.forename: Yao-Gui
authors.initials: YG
authors.lastname: Wu
mesh_terms: D001191:Arylamine N-Acetyltransferase / Q000235:genetics / Q000378:metabolism*; D015331:Cohort Studies; D004938:Esophageal Neoplasms / Q000201:enzymology* / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D010641:Phenotype; D012307:Risk Factors
chemical_list: D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human
keywords: N-acetyltransferase 2; esophageal cancer; meta analysis; risk